Current situation and suggestions concerning the implementation of MedDRA in drug monitoring in China

doi:10.19803/j.1672-8629.20240103

Abstract

Abstract: Objective To point out the problems with and challenges to the implementation of the Medical Dictionary for Regulatory Activities (MedDRA) in drug monitoring in China in order to provide reference for applications of MedDRA. Methods MedDRA was outlined. Issues and challenges facing the product itself, management mechanisms, training of users, and construction of the community of users were analyzed. Countermeasures were recommended, such as improving management mechanisms, expanding the Chinese version, building a shared coding case database, continuous review and improvement of the Chinese version of MedDRA, supplementing definitions, and increasing the content of traditional Chinese medicine. Results and Conclusion With collaborated efforts, the introduction, popularization, and implementation of MedDRA started smoothly. Due to such factors as the characteristics of MedDRA products and existing management mechanisms, there were several issues and challenges. All parties concerned needed to coordinate and work together to address related issues and challenges to make MedDRA compatible with internationally-accepted practices and achieve mutual recognition, and to promote the high-quality development of innovative drugs in China.

Key words: MedDRA, terminology, drug, postmarketing, surveillance

CLC Number:

R951

ZHU Yan, LI Qingna, ZHU Lan, XIE Jiang’an, YAO Keyu, HUANG Guangrui, YANG Xiaolin, GUAN Jian. Current situation and suggestions concerning the implementation of MedDRA in drug monitoring in China[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 746-751.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240103

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I7/746

References

[1] LU MJ, LIU YX.MedDRA and its applications in statistical analysis of adverse events[J]. Acta Pharmaceutica Sinica(药学学报), 2015, 50(11): 1396-1401.
[2] YU Y, BO BB, LI NN, et al.ICH in China: progress and prospect[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2021(10): 4-13.
[3] TIAN CH, LIU W, LIU CL, et al.Progress in implementation of ICH M1 in post-marketing monitoring of drugs in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 763-765.
[4] ZHAO-WONG AC, ZHU LL.An introduction to the Medical Dictionary for Regulatory Activities and its use[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(1): 74-78.
[5] CHEN J. Exciting Review of MedDRA User Conference[EB/OL]. (2023-12-11)[2024-02-11]. https://mp.weixin.qq.com/s/YmgFm5Ich-KYknI8EGoGjA.
[6] LIN X, GUO JJ, REN HL.Analysis of the building of adverse drug reaction term system[J]. Journal of Medical Informatics(医学信息学杂志), 2019, 40(6): 60-65.
[7] LIU J, XIE YM, GAI GZ, et al.Application analysis of adverse drug reaction terminology WHOART and MedDRA[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(24): 4728-4733.
[8] GROSSE-MICHAELIS I, PROESTEL S, RAO RM, et al.MedDRA labeling groupings to improve safety communication in product labels[J]. Therapeutic Innovation & Regulatory Science, 2023, 57(1): 1-6.
[9] HAN B, YANG GX, MO XY.Using text classification algorithm to sort out MedDRA Chinese terminology[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2023, 42(5): 331-336.
[10] CDR NMPA. Notice on Issuing the “MedDRA Coding Guidelines for Marketing Authorization Holder”[EB/OL]. (2022-05-06)[2024-02-13]. https://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202205/t20220506_49658.html.
[11] LI QN, LU F, ZHAO Y, et al.A preliminary study on establishing the set of terms for coding clinical trials of TCM based on MedDRA terminology[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(1): 53-55.
[12] LI QN, LU F, ZHAO Y, et al.Development of coding terminologies on adverse drug reactions for traditional Chinese medicine[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2018, 18(11): 1169-1172.
[13] O’HARE B. What’s New in MedDRA Version 24.0[EB/OL].[2024-02-13]. https://admin.new.meddra.org/sites/default/files/messenger/documents/000584_Messenger_March_2021.pdf.
[14] MedDRA. Information about the Japanese Translation of MedDRA[EB/OL].[2024-02-13]. https://admin.new.meddra.org/sites/default/files/page/documents/meddra-j_adjunct_file_0.pdf.
[15] ZHANG X, FENG Y, LI F, et al.Evaluating MedDRA-to-ICD terminology mappings[J]. BMC Medical Informatics and Decision Making, 2024, 23(Suppl 4): 299.
[16] WANG CY, DU XC, ZHUANG M, et al.Inspiration from the international terminology of adverse reaction to the establishment of the terminology of adverse reaction of traditional Chinese medicine[J]. Journal of Tianjin University of Traditional Chinese Medicin(天津中医药大学学报), 2023, 42(6): 786-795.
[17] YUAN L.Building a more scientific, efficient, and authoritative post-marketing drug regulatory system to enhance public medication safety[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2024(1): 6-14.